In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
After finishing at $179.1 in the prior trading day, Quest Diagnostics, Inc (NYSE: DGX) closed at $176.15, down -1.65%. In other words, the price has decreased by -$1.65 from its previous closing price. On the day, 0.96 million shares were traded. DGX stock price reached its highest trading level at $179.79 during the session, while it also had its lowest trading level at $176.03.
Ratios:
Our goal is to gain a better understanding of DGX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 45.36 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 14.07. For the most recent quarter (mrq), Quick Ratio is recorded 1.04 and its Current Ratio is at 1.13. In the meantime, Its Debt-to-Equity ratio is 0.88 whereas as Long-Term Debt/Eq ratio is at 0.79.
On April 02, 2025, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $195.
Citigroup Downgraded its Buy to Neutral on March 04, 2025, while the target price for the stock was maintained at $185.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 25 ’25 when Davis J. E. sold 55,093 shares for $192.22 per share. The transaction valued at 10,589,760 led to the insider holds 120,480 shares of the business.
Gregg Vicky B sold 1,250 shares of DGX for $239,700 on Nov 25 ’25. The Director now owns 17,037 shares after completing the transaction at $191.76 per share. On Nov 25 ’25, another insider, Davis J. E., who serves as the Officer of the company, bought 55,093 shares for $192.22 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DGX now has a Market Capitalization of 19697698816 and an Enterprise Value of 25660342272. As of this moment, Quest’s Price-to-Earnings (P/E) ratio for their current fiscal year is 20.67, and their Forward P/E ratio for the next fiscal year is 16.99. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.13. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.81 while its Price-to-Book (P/B) ratio in mrq is 2.69. Its current Enterprise Value per Revenue stands at 2.365 whereas that against EBITDA is 11.985.
Stock Price History:
The Beta on a monthly basis for DGX is 0.64, which has changed by 0.16982365 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, DGX has reached a high of $197.55, while it has fallen to a 52-week low of $148.70. The 50-Day Moving Average of the stock is -3.92%, while the 200-Day Moving Average is calculated to be -0.54%.
Shares Statistics:
The stock has traded on average 1.09M shares per day over the past 3-months and 1044910 shares per day over the last 10 days, according to various share statistics. A total of 111.00M shares are outstanding, with a floating share count of 110.73M. Insiders hold about 0.46% of the company’s shares, while institutions hold 97.64% stake in the company. Shares short for DGX as of 1764288000 were 4299681 with a Short Ratio of 3.95, compared to 1761868800 on 4614227. Therefore, it implies a Short% of Shares Outstanding of 4299681 and a Short% of Float of 4.4099998000000005.
Dividends & Splits
In the trailing 12 months, DGX’s forward annual dividend rate was 3.15, compared to 3.15 this year. Against a Trailing Annual Dividend Yield of 0.01758794. The stock’s 5-year Average Dividend Yield is 1.86. The current Payout Ratio is 39.15% for DGX, which recently paid a dividend on 2025-10-03 with an ex-dividend date of 2026-01-13. Stock splits for the company last occurred on 2005-06-21 when the company split stock in a 2:1 ratio.
Earnings Estimates
. The current rating of Quest Diagnostics, Inc (DGX) is the result of assessments by 14.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is $2.36, with high estimates of $2.55 and low estimates of $2.18.
Analysts are recommending an EPS of between $9.88 and $9.76 for the fiscal current year, implying an average EPS of $9.81. EPS for the following year is $10.38, with 17.0 analysts recommending between $10.74 and $9.87.
Revenue Estimates
12 analysts predict $2.75B in revenue for. The current quarter. It ranges from a high estimate of $2.77B to a low estimate of $2.73B. As of. The current estimate, Quest Diagnostics, Inc’s year-ago sales were $2.62BFor the next quarter, 12 analysts are estimating revenue of $2.76B. There is a high estimate of $2.8B for the next quarter, whereas the lowest estimate is $2.72B.
A total of 16 analysts have provided revenue estimates for DGX’s current fiscal year. The highest revenue estimate was $11B, while the lowest revenue estimate was $10.96B, resulting in an average revenue estimate of $10.98B. In the same quarter a year ago, actual revenue was $9.87BBased on 16 analysts’ estimates, the company’s revenue will be $11.38B in the next fiscal year. The high estimate is $11.57B and the low estimate is $11.23B.
